1356 related articles for article (PubMed ID: 32470563)
1. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol skews biased agonism at cannabinoid CB
Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.
Zhou H; Peng X; Hou T; Zhao N; Qiu M; Zhang X; Liang X
J Ethnopharmacol; 2020 Jan; 246():112218. PubMed ID: 31494202
[TBL] [Abstract][Full Text] [Related]
5. Protocol to Study β-Arrestin Recruitment by CB1 and CB2 Cannabinoid Receptors.
Soethoudt M; van Gils N; van der Stelt M; Heitman LH
Methods Mol Biol; 2016; 1412():103-11. PubMed ID: 27245896
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
7. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
8. Bioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors.
Yang Y; Vyawahare R; Lewis-Bakker M; Clarke HA; Wong AHC; Kotra LP
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751516
[TBL] [Abstract][Full Text] [Related]
9. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological potential of varinic-, minor-, and acidic phytocannabinoids.
Franco R; Rivas-Santisteban R; Reyes-Resina I; Casanovas M; Pérez-Olives C; Ferreiro-Vera C; Navarro G; Sánchez de Medina V; Nadal X
Pharmacol Res; 2020 May; 158():104801. PubMed ID: 32416215
[TBL] [Abstract][Full Text] [Related]
12. Similarities and differences upon binding of naturally occurring Δ
Raïch I; Rivas-Santisteban R; Lillo A; Lillo J; Reyes-Resina I; Nadal X; Ferreiro-Vera C; de Medina VS; Majellaro M; Sotelo E; Navarro G; Franco R
Pharmacol Res; 2021 Dec; 174():105970. PubMed ID: 34758399
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
[TBL] [Abstract][Full Text] [Related]
14. Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB
Bouma J; Broekhuis JD; van der Horst C; Kumar P; Ligresti A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2023 Dec; 218():115924. PubMed ID: 37972874
[TBL] [Abstract][Full Text] [Related]
15. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
17. Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures.
Rosenthaler S; Pöhn B; Kolmanz C; Huu CN; Krewenka C; Huber A; Kranner B; Rausch WD; Moldzio R
Neurotoxicol Teratol; 2014; 46():49-56. PubMed ID: 25311884
[TBL] [Abstract][Full Text] [Related]
18. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist.
Cascio MG; Gauson LA; Stevenson LA; Ross RA; Pertwee RG
Br J Pharmacol; 2010 Jan; 159(1):129-41. PubMed ID: 20002104
[TBL] [Abstract][Full Text] [Related]
19. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.
Dhopeshwarkar A; Murataeva N; Makriyannis A; Straiker A; Mackie K
J Pharmacol Exp Ther; 2017 Feb; 360(2):300-311. PubMed ID: 27927913
[TBL] [Abstract][Full Text] [Related]
20. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
McPartland JM; Duncan M; Di Marzo V; Pertwee RG
Br J Pharmacol; 2015 Feb; 172(3):737-53. PubMed ID: 25257544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
